{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:37:38Z","timestamp":1774507058785,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.cbi.2023.110738","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T08:58:37Z","timestamp":1696841917000},"page":"110738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["In\u2010vitro antiviral screening of some thiopyranothiazoles"],"prefix":"10.1016","volume":"386","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8713-7020","authenticated-orcid":false,"given":"Anna","family":"Kryshchyshyn-Dylevych","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danylo","family":"Kaminskyy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3322-0080","authenticated-orcid":false,"given":"Roman","family":"Lesyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"31","key":"10.1016\/j.cbi.2023.110738_bib1","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1016\/j.vaccine.2010.05.031","article-title":"The 2009 A (H1N1) Influenza virus pandemic: a review","volume":"28","author":"Girard","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.cbi.2023.110738_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1353\/bhm.2002.0022","article-title":"Updating the accounts: global mortality of the 1918-1920 \u201cSpanish\u201d influenza pandemic","volume":"76","author":"Johnson","year":"2002","journal-title":"Bull. Hist. Med."},{"issue":"4","key":"10.1016\/j.cbi.2023.110738_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.sjbs.2016.02.019","article-title":"Challenges presented by MERS corona virus, and SARS corona virus to global health","volume":"23","author":"Al-Hazmi","year":"2016","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.cbi.2023.110738_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of Coronavirus disease (COVID-19) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J. Autoimmun."},{"issue":"21","key":"10.1016\/j.cbi.2023.110738_bib5","doi-asserted-by":"crossref","first-page":"792","DOI":"10.15585\/mmwr.mm7021e3","article-title":"CDC COVID-19 Vaccine breakthrough case investigations team. COVID-19 Vaccine breakthrough infections reported to CDC - United States, January 1-April 30, 2021","volume":"70","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"5","key":"10.1016\/j.cbi.2023.110738_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Thanh","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.cbi.2023.110738_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrd703","article-title":"Strategies in the design of antiviral drugs","volume":"1","author":"De Clercq","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cbi.2023.110738_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104315","article-title":"Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic","volume":"104","author":"Negi","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"7","key":"10.1016\/j.cbi.2023.110738_bib9","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/acs.jmedchem.8b01361","article-title":"State of the art in respiratory syncytial virus drug discovery and development","volume":"62","author":"Cockerill","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2023.110738_bib10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ejmech.2017.09.031","article-title":"5-Ene-4-thiazolidinones \u2013 an efficient tool in medicinal chemistry","volume":"140","author":"Kaminskyy","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.cbi.2023.110738_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1573406415666190614101253","article-title":"Thiazole compounds as antiviral agents: an update","volume":"16","author":"Singh","year":"2020","journal-title":"Med. Chem."},{"key":"10.1016\/j.cbi.2023.110738_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.crgsc.2020.100021","article-title":"Microwave assisted green synthesis of thiazolidin-4-one derivatives: a perspective on potent antiviral and antimicrobial activities","volume":"3","author":"Saini","year":"2020","journal-title":"Curr Res Green Sustain Chem"},{"issue":"1","key":"10.1016\/j.cbi.2023.110738_bib13","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1080\/21691401.2019.1573824","article-title":"A conceptual review of rhodanine: current applications of antiviral drugs, anticancer and antimicrobial activities","volume":"47","author":"Mousavi","year":"2019","journal-title":"Artif. Cell Nanomed. Biotechnol."},{"issue":"9","key":"10.1016\/j.cbi.2023.110738_bib14","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/JVI.02325-09","article-title":"Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin","volume":"84","author":"Vanderlinden","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.cbi.2023.110738_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jhet.1056","article-title":"Synthesis and anticancer and antiviral activities of new 2-pyrazoline-substituted 4-thiazolidinones","volume":"50","author":"Havrylyuk","year":"2013","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.cbi.2023.110738_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejmech.2013.05.044","article-title":"Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones","volume":"66","author":"Havrylyuk","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.cbi.2023.110738_bib17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0014-827X(03)00024-7","article-title":"Anti-HIV agents: design and discovery of new potent RT inhibitors","volume":"58","author":"Barreca","year":"2003","journal-title":"Farmaco"},{"key":"10.1016\/j.cbi.2023.110738_bib18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40199-014-0086-1","article-title":"Synthesis, HIV-1 RT Inhibitory, antibacterial, antifungal and binding mode studies of some novel N-substituted 5-benzylidine-2,4-thiazolidinediones","volume":"23","author":"Bahare","year":"2015","journal-title":"Daru J Pharm Scis"},{"issue":"21","key":"10.1016\/j.cbi.2023.110738_bib19","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1021\/jm8008844","article-title":"Pharmacophore Modeling and molecular docking led to the discovery of inhibitors of human immunodeficiency virus-1 replication targeting the human cellular aspartic acid-glutamic acid-alanine-aspartic acid box polypeptide 3","volume":"51","author":"Maga","year":"2008","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.cbi.2023.110738_bib20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/med.20116","article-title":"HIV-1 integrase inhibitors: 2005-2006 update","volume":"28","author":"Dayam","year":"2008","journal-title":"Med. Res. Rev."},{"issue":"1","key":"10.1016\/j.cbi.2023.110738_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2036.2010.04317.x","article-title":"Review article: specifically targeted anti-viral therapy for Hepatitis C - a new era in therapy: review: HCV - STAT-C era of therapy","volume":"32","author":"Lange","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"43","key":"10.1016\/j.cbi.2023.110738_bib22","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.3748\/wjg.v13.i43.5673","article-title":"Specifically targeted antiviral therapy for Hepatitis C virus","volume":"13","author":"Parfieniuk","year":"2007","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.cbi.2023.110738_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2893.2009.01124.x","article-title":"Antiviral resistance and specifically targeted therapy for HCV (STAT-C)","volume":"16","author":"Thompson","year":"2009","journal-title":"J. Viral Hepat."},{"issue":"2","key":"10.1016\/j.cbi.2023.110738_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0960-894X(00)00610-7","article-title":"Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor","volume":"11","author":"Sing","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cbi.2023.110738_bib25","first-page":"3857","article-title":"4-Thiazolidinones: a novel class of Hepatitis C virus NS5B polymerase inhibitors","volume":"13","author":"Kaushik-Basu","year":"2008","journal-title":"Front. Biosci."},{"issue":"2","key":"10.1016\/j.cbi.2023.110738_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1469-0691.2010.03430.x","article-title":"New HCV therapies on the horizon","volume":"17","author":"Vermehren","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.cbi.2023.110738_bib27","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ejmech.2013.08.043","article-title":"2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase","volume":"69","author":"K\u00fc\u00e7\u00fckg\u00fczel","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.cbi.2023.110738_bib28","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.4155\/fmc.11.53","article-title":"Allosteric inhibition of the Hepatitis C Virus NS5B polymerase: in silico atrategies for drug discovery and development","volume":"3","author":"Barreca","year":"2011","journal-title":"Future Med. Chem."},{"issue":"22","key":"10.1016\/j.cbi.2023.110738_bib29","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1016\/j.bmcl.2006.08.056","article-title":"Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors","volume":"16","author":"Yan","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.cbi.2023.110738_bib30","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.bmcl.2007.01.024","article-title":"Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: convergence of structure-based drug design and X-Ray crystallographic study","volume":"17","author":"Yan","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cbi.2023.110738_bib31","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00044-021-02721-w","article-title":"Synthesis, docking, and biological evaluation of thiazolidinone derivatives against Hepatitis C Virus genotype 4a","volume":"30","author":"Al-Behery","year":"2021","journal-title":"Med. Chem. Res."},{"issue":"9","key":"10.1016\/j.cbi.2023.110738_bib32","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nrmicro.2017.59","article-title":"Engineering of obligate intracellular bacteria: progress, challenges and paradigms","volume":"15","author":"McClure","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"issue":"2","key":"10.1016\/j.cbi.2023.110738_bib33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.24959\/ophcj.15.819","article-title":"Screening of the antiviral activity in the range of C5 and N3 substituted 4-thiazolidinone derivatives","volume":"13","author":"Kaminskyy","year":"2015","journal-title":"J Org Pharm Chem"},{"issue":"6","key":"10.1016\/j.cbi.2023.110738_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201800330","article-title":"Synthesis and anti-coronavirus activity of a series of 1-thia-4-azaspiro[4.5]decan-3-one derivatives","volume":"352","author":"Apayd\u0131n","year":"2019","journal-title":"Arch. Pharm. (Weinheim)"},{"issue":"3","key":"10.1016\/j.cbi.2023.110738_bib35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/10426507.2020.1828886","article-title":"New spirothiazolidinone derivatives: synthesis and antiviral evaluation","volume":"196","author":"Apayd\u0131n","year":"2021","journal-title":"Phosphorus, Sulfur Silicon Relat. Elem."},{"issue":"11","key":"10.1016\/j.cbi.2023.110738_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900028","article-title":"Novel N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives as potent and selective influenza virus fusion inhibitors","volume":"352","author":"G\u00f6kta\u015f","year":"2019","journal-title":"Arch. Pharm. (Weinheim)"},{"issue":"1","key":"10.1016\/j.cbi.2023.110738_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115130","article-title":"Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones","volume":"28","author":"Cihan-\u00dcst\u00fcnda\u011f","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.cbi.2023.110738_bib38","series-title":"Proceeding of the 26th International Conference on Antiviral Research (ICAR)","first-page":"11","article-title":"Inhibition of SARS-CoV by thiazolidin-4-ones","author":"Barnard","year":"2013"},{"issue":"21","key":"10.1016\/j.cbi.2023.110738_bib39","doi-asserted-by":"crossref","first-page":"9144","DOI":"10.1021\/acs.jpclett.0c02421","article-title":"Discovery of COVID-19 inhibitors targeting the SARS-CoV-2 Nsp13 helicase","volume":"11","author":"White","year":"2020","journal-title":"J. Phys. Chem. Lett."},{"issue":"6","key":"10.1016\/j.cbi.2023.110738_bib40","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/21645515.2020.1735227","article-title":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics","volume":"16","author":"Dhama","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"issue":"5","key":"10.1016\/j.cbi.2023.110738_bib41","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.cbi.2023.110738_bib42","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jpha.2020.04.008","article-title":"Structural elucidation of SARS-CoV-2 vital proteins: computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase","volume":"10","author":"Mirza","year":"2020","journal-title":"J Pharm Anal"},{"issue":"7","key":"10.1016\/j.cbi.2023.110738_bib43","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of Pan Assay Interference Compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.cbi.2023.110738_bib44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1021\/jm201243p","article-title":"Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry","volume":"55","author":"Mendgen","year":"2012","journal-title":"J. Med. Chem."},{"issue":"7519","key":"10.1016\/j.cbi.2023.110738_bib45","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/513481a","article-title":"Chemistry: chemical con artists foil drug discovery","volume":"513","author":"Baell","year":"2014","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.cbi.2023.110738_bib46","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1080\/17460441.2017.1388370","article-title":"Recent developments with rhodanine as a scaffold for drug discovery","volume":"12","author":"Kaminskyy","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"issue":"3","key":"10.1016\/j.cbi.2023.110738_bib47","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3797\/scipharm.1204-02","article-title":"Fused thiopyrano[2,3-d]thiazole derivatives as potential anticancer agents","volume":"80","author":"Kryshchyshyn","year":"2012","journal-title":"Sci. Pharm."},{"issue":"2","key":"10.1016\/j.cbi.2023.110738_bib48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/scipharm86020026","article-title":"Thiopyrano[2,3-d]thiazoles as new efficient scaffolds in medicinal chemistry","volume":"86","author":"Kryshchyshyn","year":"2018","journal-title":"Sci. Pharm."},{"issue":"2","key":"10.1016\/j.cbi.2023.110738_bib49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/00397911.2013.800552","article-title":"5-Ethoxymethylidene-4-thioxo-2-thiazolidinone as versatile building block for novel biorelevant small molecules with thiopyrano[2,3-d][1,3]thiazole core","volume":"44","author":"Atamanyuk","year":"2014","journal-title":"Synth. Commun."},{"issue":"Special Issue","key":"10.1016\/j.cbi.2023.110738_bib50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.15407\/ubj88.si01.105","article-title":"New thiopyrano[2,3-d][1,3]thiazole derivatives as potential antiviral agents","volume":"88","author":"Zelisko","year":"2016","journal-title":"Ukrainian Biochem. J."},{"issue":"9","key":"10.1016\/j.cbi.2023.110738_bib51","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/10426507.2016.1166108","article-title":"Synthesis, anticancer and antiviral activities of novel thiopyrano[2,3-d]thiazole-6-carbaldehydes","volume":"191","author":"Lozynskyi","year":"2016","journal-title":"Phosphorus Sulfur Silicon Relat Elem"},{"key":"10.1016\/j.cbi.2023.110738_bib52","series-title":"In Modern Applications of Cycloaddition Chemistry","first-page":"pp1","article-title":"Cycloaddition reactions for antiviral compounds","author":"Quadrelli","year":"2019"},{"issue":"31","key":"10.1016\/j.cbi.2023.110738_bib53","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1016\/j.tetlet.2008.05.062","article-title":"A new domino-Knoevenagel\u2013Hetero-Diels\u2013Alder reaction","volume":"49","author":"Matiychuk","year":"2008","journal-title":"Tetrahedron Lett."},{"issue":"1","key":"10.1016\/j.cbi.2023.110738_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.15407\/ubj95.01.031","article-title":"Novel putative ligands of cannabinoid receptors: synthesis and effects on cell signaling and neuronal functions","volume":"95","author":"Senkiv J","year":"2023","journal-title":"Ukrainian Biochem. J."},{"key":"10.1016\/j.cbi.2023.110738_bib55","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1055\/s-0030-1260765","article-title":"Isorhodanine and thiorhodanine motifs in the synthesis of fused thiopyrano[2,3-d][1,3]thiazoles","volume":"10","author":"Lesyk","year":"2011","journal-title":"Synlett"},{"issue":"1","key":"10.1016\/j.cbi.2023.110738_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(00)00125-X","article-title":"In vitro and in vivo assay systems for study of influenza virus inhibitors","volume":"48","author":"Sidwell","year":"2000","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.cbi.2023.110738_bib57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1087057106296688","article-title":"Development and validation of a high-throughput screen for inhibitors of SARS CoV and its application in screening of a 100,000-compound library","volume":"12","author":"Severson","year":"2007","journal-title":"J. Biomol. Screen"},{"issue":"5","key":"10.1016\/j.cbi.2023.110738_bib58","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1128\/am.22.5.797-801.1971","article-title":"Use of disposable micro tissue culture plates for antiviral and interferon induction studies","volume":"22","author":"Sidwell","year":"1971","journal-title":"Appl. Microbiol."},{"issue":"1","key":"10.1016\/j.cbi.2023.110738_bib59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0166-3542(02)00013-X","article-title":"Identification of active antiviral compounds against a New York isolate of west nile virus","volume":"55","author":"Morrey","year":"2002","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.cbi.2023.110738_bib60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0166-0934(90)90091-S","article-title":"A microtiter virus yield reduction assay for the evaluation of antiviral compounds against Human Cytomegalovirus and Herpes Simplex Virus","volume":"28","author":"Prichard","year":"1990","journal-title":"J. Virol. Methods"},{"issue":"5","key":"10.1016\/j.cbi.2023.110738_bib61","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/jac\/44.5.705","article-title":"Cytopathic effect inhibition assay for determining the in-vitro susceptibility of Herpes Simplex Virus to antiviral agents","volume":"44","author":"Cotarelo","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.cbi.2023.110738_bib62","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.antiviral.2007.10.006","article-title":"NIAID resources for developing new therapies for severe viral infections","volume":"78","author":"Greenstone","year":"2008","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.cbi.2023.110738_bib63","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0166-3542(92)90056-B","article-title":"Use of a standardized cell culture assay to assess activities of nucleoside analogs against Hepatitis B Virus replication","volume":"19","author":"Korba","year":"1992","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.cbi.2023.110738_bib64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/scipharm86040047","article-title":"Isothiochromenothiazoles \u2013 a class of fused thiazolidinone derivatives with established anticancer activity that inhibits growth of Trypanosoma brucei brucei","volume":"86","author":"Kryshchyshyn","year":"2018","journal-title":"Sci. Pharm."},{"issue":"23","key":"10.1016\/j.cbi.2023.110738_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127616","article-title":"Assessing different thiazolidine and thiazole based compounds as antileishmanial scaffolds","volume":"30","author":"Schadich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279723004052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279723004052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:16:37Z","timestamp":1736381797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279723004052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":65,"alternative-id":["S0009279723004052"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2023.110738","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u2010vitro antiviral screening of some thiopyranothiazoles","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2023.110738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110738"}}